Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CAMP vs CBIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CBIO Captures Overall Composite Edge (42.4 HOLD vs 43.9 HOLD), While CAMP Leads 4–1 on Growth & Valuation Pillars

CBIO Overall Winner 6-Pillar Tally: CAMP 4 – 1 CBIO (1 Tie) Matrix Metrics: CAMP 4 – 3 CBIO

As of Nov 17, 2026, Crescent Biopharma, Inc. (CBIO) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (42.4/100 HOLD vs. 43.9/100 HOLD) after splitting the core matrix 3–4 (led by Options & Positioning), while CAMP wins 4–1 across the 6-pillar growth and valuation breakdown. CAMP trades at $3.95 (N/M Forward P/E, -991.8% operating margin) versus CBIO at $13.30 (N/M Forward P/E, -1228.4% operating margin).

  • Composite vs. Pillar Nuance: While CAMP currently prints a higher short-term Unified Composite Score (43.9/100 HOLD vs. CBIO 42.4/100 HOLD), CBIO captures the overall institutional head-to-head verdict (3–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-1228.4% vs. -991.8% operating margin) and revenue trajectory (+0.0% vs. +138.9% YoY).
  • Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9); meanwhile CBIO is in a Breakdown options structure phase (RSI 45.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CAMP vs CBIO
CAMP NASDAQ
CAMP4 Therapeutics Corporation Common Stock
Pharmaceutical Preparations
$3.95
+2.33% 1D
Market Cap $238.5M
TTM Revenue $5.3M
Forward P/E N/M
Beta / 30D Vol 1.34β · 94% Vol
Unified Composite Score
43.9 / 100 HOLD
Tech 34.0 Fund 40.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.9 · SMA20: $3.82 · SMA50: $3.84
CBIO NASDAQ Head-to-Head Winner
Crescent Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$13.30
-1.48% 1D
Market Cap $591.3M
TTM Revenue $15M
Forward P/E N/M
Beta / 30D Vol 1.38β · 58% Vol
Unified Composite Score
42.4 / 100 HOLD
Tech 36.0 Fund 51.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.6 · SMA20: $13.51 · SMA50: $14.51

6-Pillar Scorecard Institutional Category Breakdown (CAMP 4 – 1 CBIO)

Columns: Metric · CAMP · CBIO
1. Valuation Multiples CAMP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 26.6x 28.1x
2. Growth & Scale CAMP
Revenue Growth (YoY) +138.9% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $5.3M $15M
Market Cap $238.5M $591.3M
3. Profitability & Quality CAMP
Gross Margin N/A 100.0%
Operating Margin -991.8% -1228.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -146.1% -160.8%
4. Balance Sheet & Cash Flow CAMP
Cash Generation (TTM) -$26M -$154M
Cash Flow Margin N/A N/A
Net Cash / Leverage $97M Net Cash $170M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CBIO
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 127.8% (10th %ile)
Put/Call OI Skew N/A 1.07x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CAMP (4) vs CBIO (3)
Institutional Metric CAMP CBIO Criterion Row Edge
Market Capitalization
Scale
$238.5M $591.3M Larger Scale CBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+138.9% +0.0% Higher Growth CAMP
Operating Margin (TTM)
Profitability
-991.8% -1228.4% Higher Margin CAMP
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-146.1% -160.8% Higher ROE CAMP
52-Week Range Position
Momentum
22% ($3–$8) 24% ($9–$27) Stronger Trend CBIO
Beta / 30D Volatility
Risk Regime
1.34β · 94% Vol 1.38β · 58% Vol Lower Realized Risk CBIO
Unified Institutional Score
Composite Signal
43.9 / 100 (HOLD) 42.4 / 100 (HOLD) Higher Composite CAMP
Trailing 12M Revenue (USD)
Operating Scale
$5.3M $15M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 26.6x EV/Rev N/M PEG · 28.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$26M ($97M Net Cash) -$154M ($170M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAMP +18.19 pp
CAMP: +25.8% · CBIO: +7.61%
3M Horizon CAMP +8.16 pp
CAMP: -15.05% · CBIO: -23.21%
6M Horizon CAMP +23.21 pp
CAMP: -4.82% · CBIO: -28.03%
1Y Horizon CBIO +5.81 pp
CAMP: -3.66% · CBIO: +2.15%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CAMP Revenue CBIO Revenue CAMP Op. Margin CBIO Op. Margin Margin Leader
FY2015 N/A $20M N/A -63.7% CBIO
FY2016 N/A $0M N/A -172505.3% CBIO
FY2020 N/A $10M N/A -506.8% CBIO
FY2021 N/A $0M N/A -5470.7% CBIO
FY2022 N/A $0M N/A -63204.4% CBIO
FY2023 $0M $0M -14822.6% -392752.9% CAMP
FY2024 $0M N/A -8142.3% N/A CAMP
FY2025 $0M $10M -1502.4% -1407.5% CBIO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CAMP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CAMP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CBIO BREAKDOWN
145d in phase · OBV NEUTRAL
Current IV 127.8%
IV Percentile 10th %ile
Put/Call OI Skew 1.07x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CAMP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $591.3M market capitalization and -1228.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CAMP vs CBIO Key Questions & Quantitative Answers

As of Nov 17, 2026, Crescent Biopharma, Inc. (CBIO) captures the overall head-to-head institutional edge over CAMP4 Therapeutics Corporation (CAMP) on higher Unified Composite conviction (42.4/100 HOLD vs. 43.9/100 HOLD) after splitting the core matrix 3–4 (led by Options & Positioning), while CAMP wins 4–1 across the 6-pillar growth and valuation breakdown. CAMP trades at $3.95 (N/M Forward P/E, -991.8% operating margin) versus CBIO at $13.30 (N/M Forward P/E, -1228.4% operating margin). Composite vs. Pillar Nuance: While CAMP currently prints a higher short-term Unified Composite Score (43.9/100 HOLD vs. CBIO 42.4/100 HOLD), CBIO captures the overall institutional head-to-head verdict (3–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (-1228.4% vs. -991.8% operating margin) and revenue trajectory (+0.0% vs. +138.9% YoY). Technical & Structure Timing Caution: CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9); meanwhile CBIO is in a Breakdown options structure phase (RSI 45.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CAMP leads the Growth & Scale pillar: CAMP posts +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin), compared with CBIO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (100.0% gross margin, -1228.4% operating margin). Across the 8-period historical trajectory (FY2015 to FY2025), CAMP cumulative revenue shifted N/A while CBIO shifted -50.0%. In operating R&D and SG&A reinvestment, CAMP deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CBIO.

CAMP screens cheaper on headline valuation multiples. CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin), whereas CBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 28.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAMP (-146.1% ROE) versus CBIO (-160.8% ROE) capital efficiency.

In options market volatility and institutional positioning, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.34β · 94% Vol realized risk). By comparison, CBIO carries 127.8% implied volatility (10th %ile, Compressed (<25th %ile)), a 1.07x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.38β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.